Investment Rating - The report maintains a rating of "Accumulate" for the company with a target price of 31.27 CNY [6][12]. Core Insights - The company achieved a revenue of 4.22 billion CNY in 2025, a decrease of 4.87%, while the net profit attributable to shareholders reached 907 million CNY, an increase of 15.03% [12]. - The company is expected to continue its internal development and external expansion during the 14th Five-Year Plan period under new management [2]. - The company has successfully improved its net profit margin through cost reduction and efficiency enhancement while maintaining a high dividend policy [2]. Financial Summary - Total revenue projections for 2024A to 2028E are as follows: 4.44 billion CNY (2024A), 4.22 billion CNY (2025A), 4.62 billion CNY (2026E), 5.04 billion CNY (2027E), and 5.44 billion CNY (2028E) [4]. - Net profit attributable to shareholders is projected to grow from 788 million CNY in 2024A to 1.18 billion CNY in 2028E, with a growth rate of 15.0% in 2025A [4]. - The company’s earnings per share (EPS) is expected to increase from 1.24 CNY in 2024A to 1.86 CNY in 2028E [4]. Business Performance - The OTC segment generated revenue of 2.99 billion CNY in 2025, down 8.39%, but maintained a gross margin of 75.14%, an increase of 2.40 percentage points [12]. - Prescription drug revenue was 720 million CNY, a decrease of 9.15%, with a gross margin of 41.94%, up 2.67 percentage points [12]. - Health consumer products and other revenues increased by 43.19% to 494 million CNY, with a gross margin of 41.46%, up 3.74 percentage points [12]. Cost Management and Profitability - The company's gross margin for 2025 was 65.37%, an increase of 1.85 percentage points, attributed to business structure optimization and reduced raw material costs [12]. - Sales expenses decreased by 12.94% in 2025, with a sales expense ratio of 30.84%, down 2.86 percentage points [12]. - The net profit margin improved by 4 percentage points to 23.40% in 2025 due to enhanced gross margin and effective cost control [12]. Shareholder Returns - The company’s dividend payout ratio is expected to be 96.71% of net profit in 2025, ranking among the top in the traditional Chinese medicine sector [12]. - The controlling shareholder successfully completed a shareholding increase plan, reflecting confidence in the company's long-term development [12].

Core Viewpoint - China Resources Pharmaceutical Group Limited is a leading comprehensive pharmaceutical company in China, ranking among the top three in the industry, with a compound annual growth rate (CAGR) of 7.5% in revenue from 2019 to 2024 [1] Group 1: Pharmaceutical Manufacturing and OTC Business - The company is the largest OTC manufacturer in China, focusing on consumer health products (CHC), with traditional Chinese medicine and health products accounting for nearly 60% of revenue by mid-2025 [1] - The pharmaceutical business is expected to grow at a CAGR of 10.4% from 2022 to 2024, driven by both organic growth and acquisitions [2] - By mid-2025, the revenue from OTC traditional Chinese medicine and chemical OTC products reached 8.7 billion yuan and 2.5 billion yuan, respectively, making up 45% of the pharmaceutical business revenue [1] Group 2: Business Expansion through Acquisitions - The company expanded its business scope through acquisitions, including a 43% stake in Jiangzhong Pharmaceutical in February 2019, enhancing its position in the traditional Chinese medicine sector [2] - Acquisitions of 28% stakes in Kunming Pharmaceutical and Tasly Pharmaceutical in December 2022 and March 2025, respectively, further solidified its leadership in the traditional Chinese medicine industry [2] - The company entered the blood products sector by acquiring a 29% stake in Boya Bio-Pharmaceutical in November 2021 and expanded into medical devices with the acquisition of Nanger Technology in February 2025 [2] Group 3: Pharmaceutical Distribution - The company ranks third in the pharmaceutical distribution industry, with revenue reaching 110 billion yuan in the first half of 2025, following China National Pharmaceutical Group and Shanghai Pharmaceuticals [3] - The distribution business generated 108.3 billion yuan in revenue in the first half of 2025, with medical device revenue growing by 8% to 18 billion yuan [3] - Retail revenue reached 5.5 billion yuan in the first half of 2025, reflecting an 11% year-on-year growth, supported by the establishment of specialized pharmacies and a new retail system [3] Group 4: Financial Projections and Valuation - The company is projected to achieve net profits attributable to ordinary shareholders of 3.49 billion yuan, 3.76 billion yuan, and 4.05 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 4.0%, 7.9%, and 7.7% [3] - A price-to-earnings (PE) ratio of 8.7 times is assigned for 2026, corresponding to a market value of 35.3 billion Hong Kong dollars, indicating a 24% upside potential from the current market value of 28.5 billion Hong Kong dollars [3]

Core Insights - The eighth "Belt and Road" Traditional Chinese Medicine (TCM) Development Forum and the third OTC Brand Conference were held in Hangzhou, focusing on high-quality development in the context of the Belt and Road Initiative [2] - The forum aimed to create a high-quality platform for international exchange in TCM and OTC brands, emphasizing the integration of government, industry, academia, research, and application [2] - The OTC market in China is projected to exceed 300 billion yuan by 2024, with a compound annual growth rate of 4.6% from 2018 to 2024 [3] Group 1 - The forum gathered representatives from various countries, international organizations, regulatory bodies, industry leaders, and experts to discuss TCM innovation and the upgrading of OTC brands [2] - The president of the China Non-Prescription Drug Association highlighted the importance of TCM and the OTC industry in promoting high-quality development and public health [2] - Bayer's general manager emphasized the need for patient-centered policies that enhance product accessibility and understanding [2] Group 2 - The demand for TCM has shifted from "treating illness" to "daily health management," with consumers increasingly focusing on preventive care and wellness [3] - There are three emerging opportunities in the TCM industry: increased attention to niche categories, a rise in service-oriented consumption, and the integration of online and offline channels for consumer engagement [3] - The association aims to promote the healthy development of the OTC industry and enhance the global presence of Chinese OTC and TCM brands [3]